This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvalumab in Unresectable HCC

168 views
September 20, 2024
Comments 0
Login to view comments. Click here to Login